HomeCompareEVOK vs CL

EVOK vs CL: Dividend Comparison 2026

EVOK yields 18.18% · CL yields 2.43%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EVOK wins by $24.5K in total portfolio value
10 years
EVOK
EVOK
● Live price
18.18%
Share price
$11.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$65.3K
Annual income
$5,522.63
Full EVOK calculator →
CL
CL
● Live price
2.43%
Share price
$85.73
Annual div
$2.08
5Y div CAGR
28.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.8K
Annual income
$5,401.96
Full CL calculator →

Portfolio growth — EVOK vs CL

📍 EVOK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEVOKCL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EVOK + CL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EVOK pays
CL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EVOK
Annual income on $10K today (after 15% tax)
$1,545.45/yr
After 10yr DRIP, annual income (after tax)
$4,694.24/yr
CL
Annual income on $10K today (after 15% tax)
$206.23/yr
After 10yr DRIP, annual income (after tax)
$4,591.67/yr
At 15% tax rate, EVOK beats the other by $102.57/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EVOK + CL for your $10,000?

EVOK: 50%CL: 50%
100% CL50/50100% EVOK
Portfolio after 10yr
$53.0K
Annual income
$5,462.30/yr
Blended yield
10.30%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CL right now

EVOK
Analyst Ratings
9
Buy
3
Hold
Consensus: Buy
Price Target
$18.00
+63.6% upside vs current
Range: $18.00 — $18.00
Altman Z
-10.8
Piotroski
3/9
CL
Analyst Ratings
17
Buy
24
Hold
2
Sell
Consensus: Hold
Price Target
$92.45
+7.8% upside vs current
Range: $85.00 — $100.00
Altman Z
4.5
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EVOK buys
0
CL buys
0
No recent congressional trades found for EVOK or CL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEVOKCL
Forward yield18.18%2.43%
Annual dividend / share$2.00$2.08
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28.6%
Portfolio after 10y$65.3K$40.8K
Annual income after 10y$5,522.63$5,401.96
Total dividends collected$35.3K$18.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold
Analyst price target$18.00$92.45

Year-by-year: EVOK vs CL ($10,000, DRIP)

YearEVOK PortfolioEVOK Income/yrCL PortfolioCL Income/yrGap
1← crossover$12,518$1,818.18$11,012$312.01+$1.5KEVOK
2$15,522$2,127.13$12,196$412.95+$3.3KEVOK
3$19,073$2,464.94$13,599$549.66+$5.5KEVOK
4$23,239$2,830.78$15,288$736.64+$8.0KEVOK
5$28,089$3,223.43$17,353$995.28+$10.7KEVOK
6$33,697$3,641.30$19,926$1,357.80+$13.8KEVOK
7$40,138$4,082.45$23,194$1,873.82+$16.9KEVOK
8$47,492$4,544.69$27,439$2,621.52+$20.1KEVOK
9$55,842$5,025.61$33,088$3,727.38+$22.8KEVOK
10$65,274$5,522.63$40,806$5,401.96+$24.5KEVOK

EVOK vs CL: Complete Analysis 2026

EVOKStock

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

Full EVOK Calculator →

CLConsumer Staples

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly to a range of traditional and eCommerce retailers, wholesalers, and distributors. It also includes pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic products to manage disease conditions in dogs and cats under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Full CL Calculator →
📬

Get this EVOK vs CL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EVOK vs SCHDEVOK vs JEPIEVOK vs OEVOK vs KOEVOK vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.